公开(公告)号：US20190135799A1

公开(公告)日：2019-05-09

申请号：US16049359

申请日：2018-07-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masahiro ITO ,  Hideyuki SUGIYAMA ,  Osamu KUBO ,  Fumiaki KIKUCHI ,  Takeshi YASUI ,  Keiko KAKEGAWA ,  Zenichi IKEDA ,  Tohru MIYAZAKI ,  Yasuyoshi ARIKAWA ,  Tomohiro OKAWA ,  Jinichi YONEMORI ,  Akinori TOITA ,  Takuto KOJIMA ,  Yasutomi ASANO ,  Ayumu SATO ,  Hironobu MAEZAKI ,  Shinobu SASAKI ,  Hironori KOKUBO ,  Misaki HOMMA ,  Minoru SASAKI ,  Yasuhiro IMAEDA

IPC: C07D413/14 ,  C07D471/04 ,  A61P25/28 ,  C07D413/04 ,  C07D417/14

CPC classification number: C07D413/14 ,  A61P25/28 ,  C07D413/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20230117295A1

公开(公告)日：2023-04-20

申请号：US18075853

申请日：2022-12-06

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Koji ONO ,  Masahiro ITO ,  Toshio TANAKA ,  Moriteru ASANO ,  Takaharu HIRAYAMA ,  Jun FUJIMOTO ,  Nobuki SAKAUCHI ,  Yasuhiro HIRATA ,  Akinori TOITA ,  Nao MORISHITA ,  Hironori KOKUBO ,  Yasuhiro IMAEDA ,  Hironobu MAEZAKI ,  Douglas Robert CARY ,  Ryo MIZOJIRI ,  Nobuo CHO ,  Hiroshi BANNO ,  Hidekazu TOKUHARA ,  Yasuyoshi ARIKAWA

IPC: C07D401/14 ,  C07D403/14 ,  C07D401/12 ,  C07D471/10 ,  C07D495/10 ,  C07D405/12 ,  C07D403/12 ,  C07D213/84 ,  C07D487/10 ,  C07D405/14 ,  A61P35/00

Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20240343721A1

公开(公告)日：2024-10-17

申请号：US18635839

申请日：2024-04-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro ITO ,  Hideyuki SUGIYAMA ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Jinxing LI ,  Junsi WANG ,  Takahito KASAHARA ,  Masato YOSHIKAWA

IPC: C07D413/14 ,  A61P25/28 ,  C07D413/10

CPC classification number: C07D413/14 ,  A61P25/28 ,  C07D413/10

Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I):




wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20210363130A1

公开(公告)日：2021-11-25

申请号：US17042394

申请日：2019-03-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Koji ONO ,  Masahiro ITO ,  Toshio TANAKA ,  Moriteru ASANO ,  Takaharu HIRAYAMA ,  Jun FUJIMOTO ,  Nobuki SAKAUCHI ,  Yasuhiro HIRATA ,  Akinori TOITA ,  Nao MORISHITA ,  Hironori KOKUBO ,  Yasuhiro IMAEDA ,  Hironobu MAEZAKI ,  Douglas Robert CARY ,  Ryo MIZOJIRI ,  Nobuo CHO ,  Hiroshi BANNO ,  Hidekazu TOKUHARA ,  Yasuyoshi ARIKAWA

IPC: C07D401/14 ,  A61P35/00 ,  C07D401/12 ,  C07D405/14 ,  C07D405/12 ,  C07D213/84 ,  C07D403/14 ,  C07D403/12 ,  C07D471/10 ,  C07D487/10 ,  C07D495/10

Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20230183227A1

公开(公告)日：2023-06-15

申请号：US17952546

申请日：2022-09-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro ITO ,  Hideyuki SUGIYAMA ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Jinxing LI ,  Junsi WANG ,  Takahito KASAHARA ,  Masato YOSHIKAWA

IPC: C07D413/14 ,  A61P25/28 ,  C07D413/10

CPC classification number: C07D413/14 ,  A61P25/28 ,  C07D413/10

Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I)




wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20220098180A1

公开(公告)日：2022-03-31

申请号：US17426971

申请日：2020-01-29

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro ITO ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Hideyuki SUGIYAMA ,  Tohru MIYAZAKI ,  Yasuyoshi ARIKAWA ,  Tomohiro OKAWA ,  Jinichi YONEMORI ,  Osamu KUBO ,  Akinori TOITA ,  Takuto KOJIMA ,  Fumiaki KIKUCHI ,  Minoru SASAKI ,  Misaki HOMMA ,  Yasuhiro IMAEDA ,  Hironobu MAEZAKI ,  Shiinobu SASAKI ,  Ayumu SATO ,  Hirotaka KAMITANI ,  Yasutomi ASANO ,  Hironori KOKUBO ,  Masato YOSHIKAWA

IPC: C07D413/10 ,  C07D271/06 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20210094944A1

公开(公告)日：2021-04-01

申请号：US17030504

申请日：2020-09-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro ITO ,  Hideyuki SUGIYAMA ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Jinxing LI ,  Junsi WANG ,  Takahito KASAHARA ,  Masato YOSHIKAWA

IPC: C07D413/14 ,  C07D413/10 ,  A61P25/28

Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.